Literature DB >> 30202873

Influenza Hemagglutination-inhibition Antibody Titer as a Mediator of Vaccine-induced Protection for Influenza B.

Benjamin J Cowling1, Wey Wen Lim1, Ranawaka A P M Perera1, Vicky J Fang1, Gabriel M Leung1, J S Malik Peiris1, Eric J Tchetgen Tchetgen2.   

Abstract

BACKGROUND: The hemagglutination inhibition (HAI) assay is an established correlate of protection for the inactivated influenza vaccine. However, the proportion of vaccine-induced protection that is mediated by the post-vaccination HAI titer has not been assessed.
METHODS: We used data from a randomized, placebo-controlled trial of a split-virion inactivated influenza vaccine in children aged 6-17 years. Sera were collected before and 30 days after receipt of vaccination or placebo and tested by the HAI assay against B/Brisbane/60/2008-like (B/Victoria lineage). We fitted Cox proportional hazards models to the time to laboratory-confirmed influenza B. We used causal mediation analysis to estimate the proportion of the total effect of vaccination that was mediated by higher HAI titers.
RESULTS: We estimated that vaccine efficacy against confirmed B/Victoria infection was 68% (95% confidence interval, 33%, 88%), and post-vaccination HAI titers explained 57% of the effect of vaccination on protection.
CONCLUSIONS: The majority of the effect of inactivated influenza vaccination in children is mediated by the increased HAI titer after vaccination; however, other components of the immune response to vaccination may also play a role in protection and should be further explored. Causal mediation analysis provides a framework to quantify the role of various mediators of protection.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  correlate of protection; hemagglutination inhibition; influenza; vaccination

Mesh:

Substances:

Year:  2019        PMID: 30202873      PMCID: PMC6495017          DOI: 10.1093/cid/ciy759

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  17 in total

1.  Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children.

Authors:  Sophia Ng; Vicky J Fang; Dennis K M Ip; Kwok-Hung Chan; Gabriel M Leung; J S Malik Peiris; Benjamin J Cowling
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

2.  Influenza Hemagglutination-inhibition Antibody Titer as a Mediator of Vaccine-induced Protection for Influenza B.

Authors:  Benjamin J Cowling; Wey Wen Lim; Ranawaka A P M Perera; Vicky J Fang; Gabriel M Leung; J S Malik Peiris; Eric J Tchetgen Tchetgen
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

Review 3.  Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies.

Authors:  Edward A Belongia; Melissa D Simpson; Jennifer P King; Maria E Sundaram; Nicholas S Kelley; Michael T Osterholm; Huong Q McLean
Journal:  Lancet Infect Dis       Date:  2016-04-06       Impact factor: 25.071

4.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

5.  Comparative epidemiology of pandemic and seasonal influenza A in households.

Authors:  Gabriel M Leung; Joseph S M Peiris; Benjamin J Cowling; Kwok Hung Chan; Vicky J Fang; Lincoln L H Lau; Hau Chi So; Rita O P Fung; Edward S K Ma; Alfred S K Kwong; Chi-Wai Chan; Wendy W S Tsui; Ho-Yin Ngai; Daniel W S Chu; Paco W Y Lee; Ming-Chee Chiu
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

6.  Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong.

Authors:  Benjamin J Cowling; Sophia Ng; Edward S K Ma; Calvin K Y Cheng; Winnie Wai; Vicky J Fang; Kwok-Hung Chan; Dennis K M Ip; Susan S Chiu; J S Malik Peiris; Gabriel M Leung
Journal:  Clin Infect Dis       Date:  2010-11-10       Impact factor: 9.079

7.  Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial.

Authors:  Benjamin J Cowling; Sophia Ng; Edward S K Ma; Vicky J Fang; Hau Chi So; Winnie Wai; Calvin K Y Cheng; Jessica Y Wong; Kwok-Hung Chan; Dennis K M Ip; Susan S Chiu; J S Malik Peiris; Gabriel M Leung
Journal:  Clin Infect Dis       Date:  2012-06-05       Impact factor: 9.079

8.  Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines: A Review and Meta-Analysis of the Literature.

Authors:  W E Beyer; A M Palache; A D Osterhaus
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

9.  Quantifying Protection Against Influenza Virus Infection Measured by Hemagglutination-inhibition Assays in Vaccine Trials.

Authors:  Xiahong Zhao; Vicky J Fang; Suzanne E Ohmit; Arnold S Monto; Alex R Cook; Benjamin J Cowling
Journal:  Epidemiology       Date:  2016-01       Impact factor: 4.822

10.  Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial.

Authors:  Andrew J Dunning; Carlos A DiazGranados; Timothy Voloshen; Branda Hu; Victoria A Landolfi; H Keipp Talbot
Journal:  Clin Vaccine Immunol       Date:  2016-01-13
View more
  7 in total

1.  Influenza Hemagglutination-inhibition Antibody Titer as a Mediator of Vaccine-induced Protection for Influenza B.

Authors:  Benjamin J Cowling; Wey Wen Lim; Ranawaka A P M Perera; Vicky J Fang; Gabriel M Leung; J S Malik Peiris; Eric J Tchetgen Tchetgen
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

Review 2.  Distinguishing Causation From Correlation in the Use of Correlates of Protection to Evaluate and Develop Influenza Vaccines.

Authors:  Wey Wen Lim; Nancy H L Leung; Sheena G Sullivan; Eric J Tchetgen Tchetgen; Benjamin J Cowling
Journal:  Am J Epidemiol       Date:  2020-03-02       Impact factor: 4.897

3.  Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.

Authors:  Peter B Gilbert; David C Montefiori; Adrian McDermott; Youyi Fong; David Benkeser; Weiping Deng; Honghong Zhou; Christopher R Houchens; Karen Martins; Lakshmi Jayashankar; Flora Castellino; Britta Flach; Bob C Lin; Sarah O'Connell; Charlene McDanal; Amanda Eaton; Marcella Sarzotti-Kelsoe; Yiwen Lu; Chenchen Yu; Bhavesh Borate; Lars W P van der Laan; Nima Hejazi; Chuong Huynh; Jacqueline Miller; Hana M El Sahly; Lindsey R Baden; Mira Baron; Luis De La Cruz; Cynthia Gay; Spyros Kalams; Colleen F Kelley; Mark Kutner; Michele P Andrasik; James G Kublin; Lawrence Corey; Kathleen M Neuzil; Lindsay N Carpp; Rolando Pajon; Dean Follmann; Ruben O Donis; Richard A Koup
Journal:  medRxiv       Date:  2021-08-15

4.  Age-specific differences in the dynamics of protective immunity to influenza.

Authors:  Sylvia Ranjeva; Rahul Subramanian; Vicky J Fang; Gabriel M Leung; Dennis K M Ip; Ranawaka A P M Perera; J S Malik Peiris; Benjamin J Cowling; Sarah Cobey
Journal:  Nat Commun       Date:  2019-04-10       Impact factor: 14.919

5.  Methylated (-)-epigallocatechin 3-O-gallate potentiates the effect of split vaccine accompanied with upregulation of Toll-like receptor 5.

Authors:  Motofumi Kumazoe; Kanako Takamatsu; Fuyumi Horie; Ren Yoshitomi; Hiroki Hamagami; Hiroshi Tanaka; Yoshinori Fujimura; Hirofumi Tachibana
Journal:  Sci Rep       Date:  2021-11-29       Impact factor: 4.379

6.  Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.

Authors:  Peter B Gilbert; David C Montefiori; Adrian B McDermott; Ruben O Donis; Richard A Koup; Youyi Fong; David Benkeser; Weiping Deng; Honghong Zhou; Christopher R Houchens; Karen Martins; Lakshmi Jayashankar; Flora Castellino; Britta Flach; Bob C Lin; Sarah O'Connell; Charlene McDanal; Amanda Eaton; Marcella Sarzotti-Kelsoe; Yiwen Lu; Chenchen Yu; Bhavesh Borate; Lars W P van der Laan; Nima S Hejazi; Chuong Huynh; Jacqueline Miller; Hana M El Sahly; Lindsey R Baden; Mira Baron; Luis De La Cruz; Cynthia Gay; Spyros Kalams; Colleen F Kelley; Michele P Andrasik; James G Kublin; Lawrence Corey; Kathleen M Neuzil; Lindsay N Carpp; Rolando Pajon; Dean Follmann
Journal:  Science       Date:  2021-11-23       Impact factor: 63.714

7.  Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.

Authors:  Richard T Davey; Eduardo Fernández-Cruz; Norman Markowitz; Sarah Pett; Abdel G Babiker; Deborah Wentworth; Surender Khurana; Nicole Engen; Fred Gordin; Mamta K Jain; Virginia Kan; Mark N Polizzotto; Paul Riska; Kiat Ruxrungtham; Zelalem Temesgen; Jens Lundgren; John H Beigel; H Clifford Lane; James D Neaton
Journal:  Lancet Respir Med       Date:  2019-09-30       Impact factor: 102.642

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.